GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BTAI · Sep 30, 2024

BioXcel Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001558370-24-015629General Corporate
Operating cash generation75thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-7634.58% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-37.24% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure75thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

712.62% · OPTIONAL · VALID

Gross margin0thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.gross_margin

-446.73% · CORE · VALID

Operating margin75thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.operating_margin

-7146.26% · CORE · VALID

R&D intensity25thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

2383.64% · OPTIONAL · VALID

SBC intensity25thOwn-history percentile · N=8
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

871.50% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20246/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/8 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20267/9 normalizedLevel 3
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-2099.09%
Current
-7634.58%
Delta
-5535.49%
Growth Decreased
Previous
141.58%
Current
-37.24%
Delta
-178.82%
Inventory Pressure Increased
Previous
242.75%
Current
712.62%
Delta
469.86%
Margin Decreased
Previous
94.38%
Current
-446.73%
Delta
-541.11%
Profitability Decreased
Previous
-1566.67%
Current
-7146.26%
Delta
-5579.60%
R And D Intensity Increased
Previous
727.54%
Current
2383.64%
Delta
1656.11%
Sbc Intensity Increased
Previous
95.74%
Current
871.50%
Delta
775.75%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · BTAI Fundamental State →Transitioned To · BTAI INVENTORY_PRESSURE_INCREASED →Transitioned To · BTAI MARGIN_DECREASED →Transitioned To · BTAI PROFITABILITY_DECREASED →Transitioned To · BTAI Fundamental State →Transitioned To · BTAI CASH_GENERATION_DECREASED →Transitioned To · BTAI GROWTH_DECREASED →Transitioned To · BTAI R_AND_D_INTENSITY_INCREASED →Transitioned To · BTAI SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.